About this trial
This randomized, single-center, single-masked clinical trial aims to compare the immunomodulatory effects of sevoflurane-based inhalational anesthesia and propofol-based total intravenous anesthesia in obese patients undergoing elective lumbar instrumentation surgery. Seventy patients will be randomized into two groups: a propofol group and a sevoflurane group. Blood samples will be collected preoperatively, at postoperative 6 hours, and at postoperative 24 hours. Pentraxin-3 and serum amyloid A levels will be evaluated as primary inflammatory biomarkers together with IL-6, TNF-α, CRP, glucose, and complete blood count parameters.
Eligibility criteria
Qualifiers
Patients aged between 18 and 65 years
Patients scheduled for elective lumbar instrumentation surgery
Body mass index between 30 and 34.9 kg/m²
Patients who provided written informed consent
Disqualifiers
Known allergy to inhalational or intravenous anesthetic agents
Acute or chronic infectious disease
Autoimmune disease or immunodeficiency
Surgery within the last 3 months
Trial design
Treatments tested in this trial
- Propofol (Astra-Zeneca)
- Sevoflurane